Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Limited has set Wednesday, September 23, 2026, as the record date for determining entitlement to a final dividend for the financial year ended March 31, 2026, subject to shareholder approval at the company’s 56th Annual General Meeting scheduled for Wednesday, September 30, 2026.

Gujarat Themis Biosyn Limited (GTBL) has completed the acquisition of MicroBiopharm Japan Co., Ltd. (MBJ), Japan, through its wholly-owned subsidiary, Themis Biosyn Japan Limited (TBJ), for a total consideration of JPY 21.5 billion, funded through a mix of debt and equity. GTBL invested Rs 475 Crores towards capital contribution and Rs 745 Crores by way of loan in TBJ, and has entered into a loan agreement with TBJ for an amount up to Rs 800 Crores. The acquisition, which accelerates GTBL’s transition towards a fermentation-based, globally integrated contract development and manufacturing organization (CDMO), was made from funds managed or advised by T Capital Partners Co., Ltd.

Gujarat Themis Biosyn Limited has allotted Non-Convertible Debentures (NCDs) aggregating Rs 585 crore on a private placement basis, according to a filing with the National Stock Exchange of India and the BSE Limited on September 16, 2026. The company intends to utilize the proceeds to invest in its wholly-owned subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., Ltd, and for general corporate purposes. The NCDs consist of 58,500 debentures with a nominal value of Rs 100,000 each, split into two series: Series 1 aggregating Rs 2,950,000,000 and Series 2 aggregating Rs 2,900,000,000.

Gujarat Themis Biosyn Limited will hold a board meeting on September 10, 2026, to approve raising funds through the issue of Non-Convertible Debentures by way of Private Placement, according to a regulatory filing with the National Stock Exchange of India Limited and BSE Limited.

Gujarat Themis Biosyn Limited has closed its qualified institutions placement (QIP) on August 28, 2026, after opening it on August 25, 2026, according to a regulatory filing. The company’s Fund-Raising Committee approved an issue price of Rs 354 per equity share for 2,11,86,440 shares to be allotted to qualified institutional buyers, including a discount of Rs 18.57 on the floor price of Rs 372.57.

Gujarat Themis Biosyn Limited will hold a board meeting on September 1, 2026, to approve raising funds through the issue of equity shares and/or convertible warrants via a preferential issue on a private placement basis, according to a regulatory filing with the National Stock Exchange of India Limited and BSE Limited.

Gujarat Themis Biosyn Limited informed the Bombay Stock Exchange and National Stock Exchange that shareholders approved an amendment to the company’s Articles of Association via a Postal Ballot on August 22, 2026, specifically modifying Article 13(1) Clause (c) to allow for share purchases by any person for cash or other consideration, removing the previous requirement for valuation reports.

Gujarat Themis Biosyn Limited informed the Bombay Stock Exchange and National Stock Exchange that shareholders approved an amendment to the company’s Articles of Association at an Extraordinary General Meeting held on August 22, 2026, specifically modifying Article 13(1) Clause (c) to allow for share transfers for cash or other consideration regardless of valuation by a registered valuer.

Gujarat Themis Biosyn Limited convened an Extraordinary General Meeting on Saturday, August 22, 2026, at its registered office in Vapi, Gujarat, where shareholders approved resolutions including the approval of material related party transactions with promoter/promoter group entities, an amendment to the company’s Articles of Association, and a private placement of NCDs and/or debt securities. The meeting, chaired by Dr. Dinesh S. Patel, was attended by 56 members in person or through representatives, and remote e-voting was conducted from August 19 to August 21, 2026, with Mr. Ketan R. Shirwadkar of M/s. KRS AND CO. serving as the scrutinizer.

Sachin D. Patel disclosed to the Bombay Stock Exchange (BSE) and National Stock Exchange of India Limited (NSE) the acquisition of 5,23,560 equity shares of Gujarat Themis Biosyn Limited through an inter-se transfer among promoters and promoter group on July 30, 2026, increasing his shareholding from 2.29% to 2.77% representing 30,20,760 shares of the company's total share capital. The acquisition was made in reliance upon exemption provided for in Regulation 10 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and a prior disclosure was made on July 14, 2026.